Best Peptides for Weight Loss: Semaglutide, Tirzepatide, Retatrutide, and the New Generation of Metabolic Peptides

In the last five years, weight loss has stopped being a willpower question and started being a hormone question. The reason is a class of peptide drugs -- semaglutide, tirzepatide, and now retatrutide -- that have produced effect sizes nobody had ever seen outside of bariatric surgery. The 15-25% body weight reductions reported in the SURMOUNT and STEP trials are not the result of marketing. They are the result of finally understanding which hormones actually run the human appetite-and-energy system, and finally being able to dose them.

This guide is the most thorough survey we know of on the peptides being used for weight loss in 2026. We will cover what is actually working, what the mechanism is, how the protocols are structured, what realistic outcomes look like, and the considerations -- side effects, muscle loss, rebound, sourcing -- that you need to weigh.

This is, more than any other peptide topic, a domain where the science has outpaced the cultural conversation. Most people still think weight loss is a calories-in-calories-out moral exercise. The hormones tell a different story, and the data confirm the hormones.

Why weight management fails for so many people

To understand why peptides work where 50 years of conventional dieting has not, you have to look at what is actually broken in chronic obesity and persistent weight regain.

Body weight is regulated by a closed-loop control system in the hypothalamus. The arcuate nucleus contains two populations of neurons that operate in opposition: POMC neurons (which suppress appetite and increase energy expenditure) and AgRP/NPY neurons (which increase appetite and decrease energy expenditure). The set point of this system is determined by leptin signaling from adipose tissue, ghrelin signaling from the stomach, and a family of gut hormones released in response to nutrient intake -- principally GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and PYY.

In a person with normal weight, the system works as designed: a meal triggers GLP-1 and PYY release, satiety signals reach the hypothalamus, eating stops. Energy intake matches energy needs. In chronic obesity, several things go wrong in parallel: postprandial GLP-1 release is blunted, gastric emptying accelerates, leptin signaling becomes resistant, and the AgRP neurons fire harder. The hypothalamus is, in effect, defending a higher set point.

When someone with chronic obesity diets, they trigger a defended response. Caloric restriction produces a steeper drop in metabolic rate than the energy deficit predicts, and a steeper rise in appetite. This is the "biggest loser metabolism" pattern documented by Fothergill et al. (2016, PMID: 27136388), in which six years after the show, contestants had resting metabolic rates ~500 kcal/day below predicted. The set point had been defended, and not in a way that willpower could fix.

The GLP-1 class of peptides works because it directly addresses the broken inputs. Sustained pharmacologic GLP-1 signaling restores satiety and slows gastric emptying. Dual and triple agonists extend the same logic to GIP (which improves insulin sensitivity and glucagon signaling) and to glucagon receptor activation (which directly increases energy expenditure).

That is the biology in one paragraph. Now to the specific peptides.

How peptides address weight loss at the mechanism level

The peptides we will cover sit in four mechanistic buckets:

1. GLP-1, GIP, and glucagon receptor agonists. Semaglutide, tirzepatide, retatrutide. These are the heavy hitters; they reset the appetite and energy-expenditure control system from the top down.
2. Growth hormone fragment / lipolysis amplifiers. AOD-9604, tesamorelin (which is technically a GHRH analog). These act on adipocyte signaling and visceral fat mobilization without the broader GH side-effect profile.
3. Mitochondrial / metabolic restorers. MOTS-c, 5-Amino-1MQ. These improve substrate metabolism and energy expenditure rather than directly suppressing appetite. They are not stand-alone weight loss tools; they are stack components.
4. GH-axis amplifiers (indirect). CJC-1295 + Ipamorelin, sermorelin. These restore the overnight GH pulse, which improves body composition (more lean mass, less fat) over months. They are slow and indirect compared with the GLP-1 class but useful for the recomposition layer.

Most serious modern protocols combine a class-1 agent (for the appetite reset and the bulk of the weight loss) with one or more agents from classes 2-4 (to protect muscle, mobilize stubborn visceral fat, and improve metabolic markers).

The shortlist: peptides with the strongest weight loss evidence

Semaglutide

Semaglutide is a long-acting GLP-1 receptor agonist developed by Novo Nordisk, marketed for diabetes as Ozempic and for weight loss as Wegovy. The molecule is a modified version of native GLP-1 with two key changes: an amino acid substitution that resists DPP-4 degradation, and a fatty acid side chain that allows it to bind to albumin in the blood, extending its half-life to about a week.

The pivotal STEP 1 trial (Wilding et al., NEJM 2021, PMID: 33567185) randomized 1961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg weekly versus placebo for 68 weeks alongside lifestyle intervention. The semaglutide group lost a mean of 14.9% of body weight; placebo lost 2.4%. About one-third of the semaglutide group lost = 20% of body weight. The effect sizes are not subtle.

Subsequent STEP trials extended the findings across diabetic populations (STEP 2), maintenance after rapid weight loss (STEP 5), adolescents (STEP TEENS), and cardiovascular outcomes (SELECT, Lincoff et al., NEJM 2023, PMID: 37952131 -- which demonstrated a 20% reduction in major adverse cardiovascular events).

Mechanism summary: GLP-1 receptor activation suppresses appetite centrally via the arcuate nucleus, slows gastric emptying, and improves glucose-stimulated insulin secretion.

Typical protocol: the FDA-approved Wegovy titration starts at 0.25 mg subcutaneous weekly for 4 weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg maintenance, each step lasting four weeks. The titration is essential -- jumping doses produces the bulk of the GI side effects (nausea, vomiting) that derail roughly 5-10% of patients.

See the peptide dosing guide for the detailed protocol and semaglutide for the full profile.

Realistic outcome: in a real-world (non-trial) setting, average weight loss at one year on semaglutide 2.4 mg appears to be in the 10-13% range -- slightly below the trial numbers, probably because non-trial patients are less rigorous about the lifestyle co-intervention. Plateaus around month 12-15 are common; this is the GLP-1 system reaching a new set point, not a failure of the drug.

Tirzepatide

Tirzepatide is a dual agonist at both GLP-1 and GIP receptors, developed by Eli Lilly. Marketed for diabetes as Mounjaro and for weight loss as Zepbound. The molecule shares the albumin-binding modification with semaglutide but adds GIP receptor agonism, which appears to amplify the effect.

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022, PMID: 35658024) randomized 2539 adults with overweight or obesity (without diabetes) to tirzepatide 5, 10, or 15 mg weekly versus placebo for 72 weeks. Mean weight loss at the 15 mg dose was 20.9%, versus 3.1% on placebo. SURMOUNT-2 extended the finding into diabetic populations, with smaller (but still substantial) effects.

The mechanistic question of whether GIP agonism, antagonism, or "biased agonism" is what actually drives the additional weight loss is genuinely contested in the literature. Practically, it does not change the prescribing answer: tirzepatide produces larger weight losses than semaglutide in head-to-head comparisons.

Typical protocol: titration from 2.5 mg weekly, escalating every 4 weeks through 5, 7.5, 10, 12.5, and 15 mg. The titration matters even more than for semaglutide; the GI side effects appear earlier in the dose curve.

See tirzepatide and semaglutide for the head-to-head comparison.

Realistic outcome: at the 15 mg dose, average real-world weight loss at one year is in the 15-20% range. The price of higher efficacy is a slightly higher rate of GI side effects, particularly at dose-escalation steps.

Retatrutide

Retatrutide (Eli Lilly investigational, code LY3437943) is the new frontier: a triple agonist at GLP-1, GIP, and glucagon receptors. Adding glucagon receptor agonism, counterintuitively, drives an increase in resting energy expenditure -- the metabolic rate goes up rather than down with weight loss, which is the opposite of what happens with caloric restriction alone.

The Phase 2 trial (Jastreboff et al., NEJM 2023, PMID: 37356073) reported mean weight loss of 24.2% at 48 weeks in the 12 mg dose arm. That is approaching bariatric surgery territory in a once-weekly injection. Phase 3 trials (TRIUMPH program) are ongoing as of 2026 and have so far supported the Phase 2 findings.

Mechanism: GLP-1 suppresses appetite. GIP improves insulin sensitivity and may amplify GLP-1's central effects. Glucagon receptor activation directly increases energy expenditure and promotes lipolysis. The combination produces a unique pharmacological profile: weight loss without the metabolic-rate suppression that defeats most diets.

Typical protocol: approved dosing has not yet been finalized as of this writing; trial protocols titrate from 0.5 mg or 1 mg weekly up to 12 mg over 8-12 weeks.

See retatrutide for the full profile and the peptide stacking guide for combinations and protocol design.

AOD-9604

AOD-9604 is a synthetic peptide consisting of amino acids 176-191 of human growth hormone -- the "lipolytic fragment." It was originally developed at Monash University as an anti-obesity drug; it failed to hit its primary endpoints in human trials at the doses tested, but it remains in the peptide research and practitioner literature as a fat-loss adjunct.

The mechanism: AOD-9604 binds to beta-3 adrenergic receptors on adipocytes (in animal studies) and stimulates lipolysis -- the breakdown of stored triglycerides into free fatty acids -- without producing the broader GH effects (insulin resistance, IGF-1 elevation) that limit GH itself as an obesity intervention.

The clinical efficacy in humans is more modest than the marketing implies. A 12-week trial in obese subjects (Heffernan et al., 2001, PMID: 11717261) reported small but statistically significant fat loss; later trials showed inconsistent effects. The realistic picture is: AOD-9604 is not a primary weight loss agent. It is a stack component, useful in body recomposition contexts and possibly useful for stubborn fat depots, but it will not move the needle the way a GLP-1 will.

Typical protocol: 300-600 mcg subcutaneous daily, on an empty stomach in the morning, for 12-16 weeks.

See AOD-9604 for the full product profile and dosing detail.

Tesamorelin

Tesamorelin is a stabilized GHRH analog originally developed and approved (as Egrifta) for HIV-associated lipodystrophy -- specifically, visceral adipose tissue accumulation. The trials in that population (Falutz et al., NEJM 2007, PMID: 17893215) showed selective reduction in visceral fat without significant subcutaneous fat loss.

That selectivity is what makes tesamorelin interesting for the broader weight loss conversation. Visceral fat is the metabolically dangerous fat -- the kind associated with cardiovascular risk, hepatic steatosis, and insulin resistance. A peptide that preferentially reduces it has value even in non-HIV populations.

Mechanism: as a GHRH analog, tesamorelin amplifies the pituitary GH pulse, which raises IGF-1 and drives lipolysis preferentially from visceral fat depots (which are more lipolytically active than subcutaneous fat).

Typical protocol: 1-2 mg subcutaneous daily, evening, 4-6 month course.

See tesamorelin and the dosing guide for daily protocol details.

MOTS-c

MOTS-c, the 16-amino-acid mitochondrial-derived peptide, has data supporting effects on insulin sensitivity, glucose uptake, and lean-mass preservation. Lee et al. (Cell Metab 2015, PMID: 25738459) demonstrated improved metabolic parameters and reduced obesity in mouse models.

In a weight loss context, MOTS-c is not a primary tool but a stack adjunct, particularly for patients whose obesity is associated with mitochondrial dysfunction and insulin resistance. See MOTS-c for the full profile.

5-Amino-1MQ

5-Amino-1MQ (5-Amino-1-methylquinolinium) is a small molecule, technically not a peptide, but frequently included in peptide-adjacent stacks. Its mechanism is inhibition of nicotinamide N-methyltransferase (NNMT), an enzyme that depletes NAD+ in adipose tissue. NNMT inhibition increases NAD+ availability and thereby improves adipocyte metabolic function.

Preclinical work (Kraus et al., 2014, PMID: 24717508) demonstrated reduced adiposity and improved insulin sensitivity in NNMT-knockdown mouse models. Human clinical data is preliminary; the mechanism is well-established, the doses and protocols are still being worked out.

Typical protocol: 50-150 mg orally daily, 8-12 week cycles.

See 5-Amino-1MQ for the full product profile and current dosing protocols.

CJC-1295 + Ipamorelin (the GH pair)

The CJC-1295/Ipamorelin pair, covered in detail at cjc 1295 vs sermorelin and at ipamorelin, does not produce dramatic weight loss as a standalone. What it does is restore the natural overnight GH pulse, which over months produces improvements in body composition -- more lean mass, less fat -- that are not captured by the scale alone.

For body recomposition stacks alongside a GLP-1 (to protect muscle during weight loss, see below), the GH pair is a frequent addition. See best peptides for muscle preservation.

Stacking: combinations that synergize, and the muscle-loss problem

The dominant question in 2026 weight-loss-peptide practice is not whether the GLP-1 class works -- it does, dramatically -- but what to stack alongside it. The biggest concern is muscle loss.

GLP-1 and dual-agonist peptides produce weight loss; they do not specifically produce fat loss. The trial data show that roughly 25-40% of the weight lost on semaglutide or tirzepatide is lean mass. That is a serious concern for long-term metabolic health, sarcopenia risk, and rebound: lost muscle drops resting metabolic rate, which makes regain easier when the drug is discontinued.

Three stacks have emerged to address this:

Stack 1: GLP-1 + GH pair (CJC-1295 + Ipamorelin) for muscle preservation.

• Semaglutide or tirzepatide at standard titration
• CJC-1295 (no DAC) 100 mcg + Ipamorelin 200 mcg, 5 nights/week, at bedtime
• Mandatory resistance training, 3-4 sessions per week
• High protein intake (1.6-2.2 g/kg of target body weight)

The GH pair amplifies the overnight GH pulse, which under conditions of resistance training and adequate protein helps to preserve muscle. The lifestyle pieces are not optional -- they are doing the heavy lifting.

Stack 2: GLP-1 + Tesamorelin for visceral fat targeting.

• Semaglutide at standard titration
• Tesamorelin 1-2 mg/day evening, 4-month course
• Used when visceral adiposity is the priority and the patient has a NAFLD-spectrum profile

Stack 3: GLP-1 + MOTS-c + 5-Amino-1MQ for metabolic restoration.

• Semaglutide at lower dose (1.0-1.7 mg)
• MOTS-c 10 mg, 2x/week
• 5-Amino-1MQ 100 mg oral daily

This is the protocol most often used when the primary problem is metabolic syndrome rather than excess weight per se. The GLP-1 lowers the appetite floor; the MOTS-c and 5-Amino-1MQ improve mitochondrial and adipocyte function so that the weight loss happens against a better metabolic background.

Microdosing GLP-1. A separate practice -- microdosing semaglutide or tirzepatide at well below the FDA-approved weight-loss doses (e.g., 0.5 mg semaglutide weekly indefinitely) -- has emerged as a body-recomposition / metabolic-health tool rather than a weight-loss tool per se. The mechanistic case is that low-dose GLP-1 signaling improves insulin sensitivity and modestly reduces appetite without producing the dramatic weight loss (or the dramatic side effects). The clinical data on microdosing is anecdotal. See glp 1 microdosing explained for the full discussion.

Combinations to avoid:

• Two GLP-1 agonists at once. Pick one; do not stack semaglutide with tirzepatide. Receptor saturation is reached at therapeutic doses of either.
• GLP-1 + stimulant weight-loss drugs (phentermine, bupropion-naltrexone). Possible, but the GI side-effect profile compounds and the appetite suppression becomes excessive (anorexia is a clinical concern).
• High-dose GH or IGF-1 LR3 alongside GLP-1 without medical supervision. The metabolic axis is complex enough on a GLP-1; adding direct GH/IGF-1 raises the risk profile substantially.

Protocols: beginner, intermediate, advanced

Beginner: simple GLP-1 protocol with proper titration

For someone who is new to weight-loss peptides and has 30+ pounds to lose:

• Semaglutide 0.25 mg weekly for 4 weeks
• Increase to 0.5 mg for 4 weeks
• Continue increasing every 4 weeks until you reach the dose that produces adequate satiety with tolerable side effects (often 1.0-1.7 mg, sometimes 2.4 mg)
• Maintain at that dose for 6-12 months
• Resistance training 3x/week (non-negotiable) and protein at 1.6 g/kg of target body weight
• Re-evaluate every 3 months

Anchor expectations: 10-15% weight loss at one year is a strong real-world result.

Intermediate: GLP-1 + muscle protection stack

For someone who is concerned about muscle loss, has training experience, and wants the cleanest possible recomposition:

• Tirzepatide titration from 2.5 mg up to a tolerable maintenance dose
• CJC-1295 (no DAC) 100 mcg + Ipamorelin 200 mcg, 5 nights/week, at bedtime, fasted protocol
• Resistance training 4x/week
• Protein at 2.0-2.2 g/kg target body weight
• Creatine 5 g/day
• Re-evaluate body composition (DEXA or BIA) every 3 months

Advanced: GLP-1 + Tesamorelin + GH pair (clinical supervision recommended)

For someone with significant visceral adiposity, metabolic syndrome, NAFLD-spectrum profile, and clinical supervision:

• Semaglutide 1.7 mg weekly
• Tesamorelin 1-2 mg/day evening, 4-month course
• CJC-1295/Ipamorelin 5x/week as above
• Resistance training, high-protein diet
• Quarterly blood panel: lipid panel, A1c, fasting insulin, IGF-1, LFTs, comprehensive metabolic panel

This is not a do-it-yourself protocol. The hormonal layering is significant and the labs need to be tracked.

The "GLP-1 microdose for metabolic health" protocol

For someone at normal weight or modestly overweight who wants the metabolic benefits without the dramatic weight loss:

• Semaglutide 0.25-0.5 mg weekly, ongoing
• No titration needed
• No specific resistance training requirement (though always beneficial)
• Quarterly labs

This is the use case that has expanded the GLP-1 audience most dramatically since 2024.

What the research actually shows

The most under-discussed finding in this table is the difference between weight loss and body recomposition. The GLP-1 class produces the largest weight loss. The GH pair produces the largest body composition change relative to scale weight. For people whose health concern is metabolic, recomposition matters more than the scale.

Side effects, safety, and what to monitor

GLP-1 / GIP / glucagon agonists (semaglutide, tirzepatide, retatrutide):

• GI: nausea (most common), vomiting, constipation, diarrhea. These are the dominant side effects, particularly during dose escalation. Slow titration substantially reduces incidence. See peptide side effects weight loss.
• Pancreatitis: signal in early trials; absolute risk is small but real. History of pancreatitis is a contraindication.
• Gallbladder disease: rapid weight loss of any kind raises gallstone risk. GLP-1 agents appear to slightly amplify this.
• Thyroid C-cell hyperplasia: demonstrated in rodent studies; not clearly demonstrated in humans, but personal or family history of medullary thyroid carcinoma or MEN-2 syndrome is a hard contraindication.
• Muscle loss: as covered above -- 25-40% of lost weight is lean mass without protective measures.
• Rebound on discontinuation: the STEP-4 trial (Rubino et al., JAMA 2021, PMID: 33755728) showed substantial regain after semaglutide discontinuation. The drug is generally considered indefinite-use for chronic obesity, like a statin for cholesterol.

Tesamorelin:

• Fluid retention, joint stiffness (GH effects)
• Modest IGF-1 elevation, which warrants monitoring with prolonged use

AOD-9604:

• Generally well-tolerated; mild GI symptoms reported

MOTS-c, 5-Amino-1MQ:

• Limited long-term human data; reasonable short-cycle safety

Lab monitoring for any extended protocol:

• Baseline: comprehensive metabolic panel, A1c, fasting insulin, lipid panel, LFTs, IGF-1, TSH
• Recheck every 3 months
• DEXA body composition every 6 months ideally

Sourcing and quality

Both pharmaceutical (FDA-approved) and "research peptide" sources exist for semaglutide and tirzepatide. The pharmaceutical pathway involves a prescribing clinician, an in-network or compounding pharmacy, and (since the 2023-2024 shortages resolved) generally reliable supply.

The research-peptide pathway involves third-party suppliers selling "for research use only." Purity, dose accuracy, and sterility vary substantially. The same COA-and-third-party-testing rules apply as elsewhere on the site. See how to spot counterfeit peptides and peptide purity 99 vs 98 percent.

Counterfeit semaglutide has been a significant issue in 2024-2025; the FDA has issued multiple warnings. The Peptide.best marketplace's COA requirement is, in part, a direct response to this. See coa certificate of analysis what to look for.

For retatrutide as of 2026: there is no FDA-approved pharmaceutical version yet (Phase 3 trials ongoing). All retatrutide currently on the market is research-use-only material. Sourcing requires particular care.

FAQs

How fast does weight loss start on GLP-1 peptides?

Most people see initial weight loss within the first 2-4 weeks, with the rate accelerating once the maintenance dose is reached. Plateau timing varies: month 6-9 for semaglutide, month 9-12 for tirzepatide, longer for retatrutide.

Will I regain weight if I stop?

Yes, in most cases. The STEP-4 trial showed that two-thirds of weight lost is regained within a year of discontinuation. The GLP-1 class is being used clinically as a long-term medication, not a course of treatment.

Can I just take a "natural GLP-1 booster"?

The dietary and supplement-based "GLP-1 enhancers" (berberine, certain fibers, certain peptide nutraceuticals) produce a small fraction of the pharmacological effect. They are not in the same conversation as semaglutide-class drugs.

Are peptides safer than Ozempic?

"Peptides" and "Ozempic" are the same thing for the molecule that matters here -- Ozempic is semaglutide. The question that is usually being asked is whether research-peptide-sourced semaglutide is safer than pharmaceutically-sourced semaglutide; the answer is unambiguously no. Pharmaceutical sourcing is more reliable. See semaglutide for sourcing and verification detail.

Will peptides help with cravings, or only with hunger?

The GLP-1 class addresses both physiological hunger and "food noise" -- the cognitive preoccupation with food that many obese patients describe. The food noise reduction is, for many people, the more striking subjective change.

Can I take peptides if I am not significantly overweight?

This is the microdosing question. Microdose semaglutide and tirzepatide are being used in normal-weight and modestly overweight populations for metabolic health rather than weight loss per se. The risk-benefit calculation is different. See glp 1 microdosing explained.

Can I exercise on GLP-1 peptides?

Yes, and you should. Resistance training is the single most important adjunct to peptide-based weight loss because it preserves muscle. The frequent complaint of fatigue or reduced workout capacity in the first 2-4 weeks usually resolves with dose stabilization and adequate protein intake.

What is the difference between Ozempic, Wegovy, Mounjaro, and Zepbound?

Ozempic and Wegovy are both semaglutide; Ozempic is FDA-approved for diabetes, Wegovy for chronic weight management (higher dose). Mounjaro and Zepbound are both tirzepatide with the same dose/indication split.

Will peptides interact with my other medications?

GLP-1 agents slow gastric emptying, which can alter the absorption of some oral medications. Most clinically important interactions are with diabetes medications (risk of hypoglycemia when combined with insulin or sulfonylureas) and with medications that have narrow therapeutic windows (e.g., warfarin). Speak to a clinician.

Can I drink alcohol on GLP-1 peptides?

Many patients report a striking reduction in desire for alcohol on GLP-1 agents -- this is now an active research area for alcohol use disorder. The GI side effects of GLP-1 agents are also amplified by alcohol consumption.

How long is the typical course?

For chronic obesity, indefinite. For metabolic-health microdosing, indefinite. For pre-event weight loss or specific recomposition goals, 6-12 months with planned discontinuation and a maintenance plan (which is harder than it sounds).

References

1. Wilding JPH, Batterham RL, Calanna S, et al. *Once-weekly semaglutide in adults with overweight or obesity*. N Engl J Med. 2021. PMID: 33567185.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. *Tirzepatide once weekly for the treatment of obesity*. N Engl J Med. 2022. PMID: 35658024.
3. Jastreboff AM, Kaplan LM, Frias JP, et al. *Triple-hormone-receptor agonist retatrutide for obesity*. N Engl J Med. 2023. PMID: 37356073.
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. *Semaglutide and cardiovascular outcomes in obesity without diabetes*. N Engl J Med. 2023. PMID: 37952131.
5. Rubino D, Abrahamsson N, Davies M, et al. *Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity*. JAMA. 2021. PMID: 33755728.
6. Fothergill E, Guo J, Howard L, et al. *Persistent metabolic adaptation 6 years after "The Biggest Loser" competition*. Obesity. 2016. PMID: 27136388.
7. Falutz J, Allas S, Blot K, et al. *Metabolic effects of a growth hormone-releasing factor in patients with HIV*. N Engl J Med. 2007. PMID: 17893215.
8. Heffernan M, Summers RJ, Thorburn A, et al. *The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta-AR receptor-deficient mice*. Endocrinology. 2001. PMID: 11717261.
9. Lee C, Zeng J, Drew BG, et al. *The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance*. Cell Metab. 2015. PMID: 25738459.
10. Kraus D, Yang Q, Kong D, et al. *Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity*. Nature. 2014. PMID: 24717508.

Ready to start?

The weight-loss peptide landscape has changed more in the last five years than in the previous fifty. The science is real, the effect sizes are real, and the considerations are also real -- muscle loss, rebound, sourcing, side effects, cost.

Three reads to take next:

• semaglutide and tirzepatide profiles to choose between the two leading agents
• best peptides for muscle to plan the muscle-protection layer
• the dosing guide for the dose-escalation specifics

And the individual peptide profiles:

• semaglutide
• tirzepatide
• retatrutide
• tesamorelin

When you are ready to source, the Peptide.best marketplace requires per-batch COAs from every listed vendor of semaglutide and tirzepatide research material -- a direct response to the counterfeit problem of the last 18 months.

Weight loss is, at last, a domain where the right tool meaningfully changes the result. The work now is using the tool with discipline.